Night Time Severe Cold and Cough Relief (Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl)
Brand Names: Night Time Severe Cold and Cough Relief
Methodology & AI Transparency ⓘ
Night Time Severe Cold and Cough Relief (Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Night Time Severe Cold and Cough Relief (Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl) represents a over-the-counter branded histamine-1 receptor antagonist entry registered by Chain Drug Consortium, LLC with package codes 68016-154, 0363-9130.
- 2 Real-world patient consensus: Branded histamine-1 receptor antagonist presentation of Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl (Chain Drug Consortium, LLC); generic reference RxCUI 1298348.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $9.90 cash mean against $34.50 retail pharmacy pricing.
- 4 Top reported side effects / signs: Most commonly reported Night Time Severe Cold and Cough Relief (Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl) tolerability events: headache (8.9%), cough (5.9%), application-site irritation (5%).
Ask our AI Specialists anything about Night Time Severe Cold and Cough Relief (Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl)
Night Time Severe Cold and Cough Relief (Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl) Mechanism, CYP450 Pathways & DailyMed Monograph
Night Time Severe Cold and Cough Relief (Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl) represents a over-the-counter branded histamine-1 receptor antagonist entry registered by Chain Drug Consortium, LLC with package codes 68016-154, 0363-9130. Reviewed against 2024-12-29 FDA SPL standards (650 mg/20mL / 25 mg/20mL Liquid; 325 mg/15mL / 12.5 mg/15mL Liquid), clinical deployment addresses Uses temporarily relieves these common cold and flu symptoms: minor aches and pains headache sore throat nasal and sinus.
Night Time Severe Cold and Cough Relief achieves therapeutic action via Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl, engaging histamine-1 receptor antagonist physiological pathways with class-characteristic hepatorenal disposition. Manufactured in 650 mg/20mL / 25 mg/20mL Liquid; 325 mg/15mL / 12.5 mg/15mL Liquid (registered by Chain Drug Consortium, LLC, NDC 68016-154, 0363-9130), pharmacists evaluate FDA Orange Book therapeutic equivalence when comparing branded Night Time Severe Cold and Cough Relief ($34.50 retail) with generic Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl ($9.90 low cash).
Pharmacokinetic profiling of Night Time Severe Cold and Cough Relief (Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl) demonstrates an elimination half-life of Mean elimination half-life of 7 to 18 hours across adult Night Time Severe Cold and Cough Relief (Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl) dosing with Oral fraction absorbed ranges from 75% to 87% (Night Time Severe Cold and Cough Relief (Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl) 650) systemic bioavailability; clearance proceeds via dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of night time severe cold and cough relief (acetaminophen, diphenhydramine hcl, phenylephrine hcl), reaching clinical onset within oral tmax achieved within 2 to 4 hours following night time severe cold and cough relief (acetaminophen, diphenhydramine hcl, phenylephrine hcl) ingestion.
Titration schedules for Night Time Severe Cold and Cough Relief (Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl) (650 mg/20mL / 25 mg/20mL Liquid → 325 mg/15mL / 12.5 mg/15mL Liquid → 325 mg/1 / 25 mg/1 Tablet, Film Coated → 650 mg/30mL / 25 mg/30mL Liquid → 650 mg/237mL / 25 mg/237mL Powder, for Solution) require excluding contraindicated in patients with prior serious allergic response to night time severe cold and cough relief (acetaminophen, diphenhydramine hcl, phenylephrine hcl) (ndc 68016-154); severe baseline organ impairment where acetaminophen, diphenhydramine hcl, phenylephrine hcl accumulation exceeds safe therapeutic margins; real-world patient logs highlight headache (8.9% of reports), nausea (8.5% of reports), dizziness (6.7% of reports) alongside a 90.00% Worth-It consensus.
Reconcile eGFR-adjusted medications before escalating Night Time Severe Cold and Cough Relief (Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl) in polypharmacy regimens.
Unstandardized herbal extracts may interact pharmacodynamically with Night Time Severe Cold and Cough Relief (Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl) maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Night Time Severe Cold and Cough Relief (Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl) (NDC 68016-154)
- Severe baseline organ impairment where Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (6 Reports)
Night Time Severe Cold and Cough Relief (Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Night Time Severe Cold and Cough Relief (Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due: What a 952-Participant Study Found Pooled data confirm the safety and tolerability of fezolinetant over 52 weeks. Advances in therapy • 2025-02-15 • Meta-Analysis | N = 952 | 97/100 | PMID 39739195 ↗ |
| New Insights on Evaluating the real-world benefits and safety of SpikoGen®, an: What a 4,219-Participant Study Found 12 657 and 4219 participants were randomized to the SpikoGen® and placebo group and followed for a median of 55 days (interquartile range, 48-60 days) and 51 days. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases • 2023-02-15 • Phase III Randomized Trial | N = 4,219 | 96/100 | PMID 36096430 ↗ |
| Check Your Medicine Cabinet: Tonight We Ride, LLC Issues Voluntary Recall of Ultimate Forza Male Supplement Due to Pr October 24, 2026, Tonight We Ride, LLC of Lakeville, Minnesota is voluntarily recalling all lots of Ultimate Forza Male Supplement capsules to the consumer level because it has been found to contain undeclared Sildenafil, Tadalafil, and Dapoxetine. FDA Drug Recalls • 2026-10-24 • FDA Recall | Multi-cohort | 95/100 | PMID FDA_RECALLS-743098658 ↗ |
| New Insights on Baricitinib Withdrawal and Retreatment in Patients With Severe hair loss Areata:: What a 654-Participant Study Found Of 654 patients who received treatment, the mean (SD) age was 37.1 (13.0) years, and there were 383 women (58.6%). JAMA dermatology • 2024-10-01 • Phase III Randomized Trial | N = 654 | 93/100 | PMID 39141364 ↗ |
| New Insights on SLE-DAS enables an accurate definition of severe lupus disease activity:: What a 438-Participant Study Found The SLE-DAS cut-off for SDA provides an accurate definition of SDA in SLE, with good discriminative power and consistent associations with worse HR-QoL. Lupus science & medicine • 2025-05-16 • Phase III Randomized Trial | N = 438 | 93/100 | PMID 40379439 ↗ |
Night Time Severe Cold and Cough Relief (Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.0194/unit (~$0.58/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 6 Anonymous DotMD Community Micro-Logs | $9.90 / mo | View logs ↓ |
Night Time Severe Cold and Cough Relief (Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Night Time Severe Cold and Cough Relief (Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl) RxNorm Concept ID | 1298348 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0194 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $9.90 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 90.00% Worth It (6 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Night Time Severe Cold and Cough Relief (Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Night Time Severe Cold and Cough Relief (Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl) (histamine-1 receptor antagonist) monograph synthesizing RxNorm 1298348, openFDA FAERS signals, and $9.90–$34.50 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Night Time Severe Cold and Cough Relief (Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl) community threads and patient logs by age, biological sex, dosage, and treatment duration.